← Issue №17/ week of Oct 25, 2026/Hepatology

Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC, Warfarin and Non-Anticoagulated Patients.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=11,387 · Oct 22, 2026 · Aliment Pharm Ther · IF 6.7

Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC, Warfarin and Non-Anticoagulated Patients.

New evidenceepidemiology
Clinical takeawayRisk-stratify GI bleeding on severity and patient factors (age, shock, renal failure) rather than anticoagulant status; the anticoagulant estimates were imprecise (30-day OR 1.61, 95% CI 0.81-3.21 for DOAC), so a modest effect is not excluded.
What it foundNeither DOAC nor warfarin was significantly associated with 30-day or 1-year mortality after GIB (30-day OR 1.61, 95% CI 0.81-3.21 for DOAC; 1.30, 95% CI 0.56-3.02 for warfarin).
ContextChallenges the assumption that anticoagulation status drives mortality in GIB, refining risk stratification to include clinical presentation and comorbidities.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Forkosh E … Talmon A · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues